Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol for Angina with Coronary Microvascular Dysfunction
NCT06755801Phase 3Not yet recruiting
- Sponsor
- Sociedad Española de Cardiología
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in angina pectoris and Coronary Microvascular Dysfunction (CMD) comparing Nebivolol with Placebo (2 arms). Primary endpoint: Seattle Angina Questionnaire at 6 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
nebivolol
03
Conditions
angina pectorisCoronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT06755801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06755801.